Naloxone Polpharma (Naloxone Hydrochloride)

Naloxone Hydrochloride binds competitively to mu‑opioid receptors without activating them, displacing opioid agonists such as morphine or fentanyl. This blocks the opioids’ effects, quickly reversing respiratory depression, sedation, and analgesia associated with overdose.

The specific dose is determined by the prescribing clinician based on the patient’s condition, the opioid involved, and the route of administration. In emergency settings, clinicians may administer an initial dose and repeat as needed, following local protocols.

Safety data in pregnancy and lactation are limited. Naloxone should be used only if the potential benefit justifies any possible risk to the fetus or infant. Clinicians should evaluate each case individually and monitor both mother and child closely.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Naloxone Polpharma is an injectable formulation comparable in efficacy to other naloxone injection products. Differences may lie in packaging, concentration, and regulatory approvals. All injectable naloxone products act on the same receptors, but clinicians may choose a specific brand based on availability, cost, or institutional preference.

Store the injection solution at 2‑8 °C in a refrigerator. Protect it from light, do not freeze, and avoid shaking the vial. Keep the product in its original packaging until use to maintain stability and potency.

Naloxone Polpharma is administered by a healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route is selected based on the clinical situation, with intramuscular injection often used in pre‑hospital settings and intravenous preferred in hospital emergencies.

Serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, seizures, anaphylaxis, and acute opioid withdrawal syndrome, which can cause agitation, vomiting, or tachycardia. Patients should be monitored continuously for these events after administration.

Naloxone Polpharma should be avoided in individuals with a known hypersensitivity to naloxone or any component of the formulation. Caution is also advised for patients with severe cardiovascular disease, as rapid reversal of opioid effects can precipitate abrupt hemodynamic changes.